Sweden’s BioArctic today revealed that the US Federal Trade Commission (FTC) has cleared the proposed deal with Bristol Myers ...
BioArctic’s global license agreement with Bristol Myers Squibb for PyroGlu-Aß antibody programme effective after antitrust clearance and closing: Stockholm, Sweden Saturday, Fe ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement has been reached. The milestone was reached as ...
Eisai announces Leqembi sales reaches €200 million; BioArctic to receive €10 million payment: Stockholm, Sweden Wednesday, February 19, 2025, 14:00 Hrs [IST] BioArctic AB’s ...
STOCKHOLM, Feb. 18, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement ...
STOCKHOLM, Feb. 18, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement ...
Novo Nordisk A/S was the biggest leader among large stocks during the session, gaining 5.8%, and DNO ASA gained 5.4%. Carlsberg A/S Series A rounded out the top three leaders on Friday, with shares ...
VIVOZON Pharmaceutical announced that its non-opioid analgesic, UNAFRA Inj., was approved on December 12, 2024. (Active ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback